Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000231223 | SCV000284533 | benign | Neurofibromatosis, type 1 | 2024-09-23 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002311337 | SCV000663006 | uncertain significance | Hereditary cancer-predisposing syndrome; Cardiovascular phenotype | 2022-08-30 | criteria provided, single submitter | clinical testing | The c.848A>G (p.D283G) alteration is located in exon 8 (coding exon 8) of the NF1 gene. This alteration results from a A to G substitution at nucleotide position 848, causing the aspartic acid (D) at amino acid position 283 to be replaced by a glycine (G). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Genome- |
RCV000231223 | SCV002561835 | uncertain significance | Neurofibromatosis, type 1 | 2022-03-15 | criteria provided, single submitter | clinical testing | |
Baylor Genetics | RCV004567718 | SCV005052271 | uncertain significance | Juvenile myelomonocytic leukemia | 2024-01-06 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV005016620 | SCV005647000 | uncertain significance | Neurofibromatosis, familial spinal; Juvenile myelomonocytic leukemia; Neurofibromatosis, type 1; Neurofibromatosis-Noonan syndrome; Café-au-lait macules with pulmonary stenosis | 2024-02-06 | criteria provided, single submitter | clinical testing |